On the desk today · Ecolab
The dispenser on the wall. The truck in the parking lot. The check that comes every month.
| NYSE · ECL |
Elon Musk did it again! After self-driving cars…
Reusable rockets that land themselves…
And brain chips that let paralyzed people control computers with their minds…
A new form of AI so powerful he called it an "infinite money glitch."
And it could help send shares of this little-known Elon Musk supplier to the moon.
The Company That Cleans
Everything You Touch
In 1923, a salesman in St. Paul, Minnesota, had a problem nobody else was solving. Hotels had to shut down entire floors to clean their carpets. Guests were turned away. Revenue was lost. A man named Merritt J. Osborn invented a product called Absorbit — a powder that cleaned carpets on the spot, no closure required. He called his company Economics Laboratory. The name said it all: economic solutions, built in a lab. Save the customer time. Save the customer money. Get the check.
One hundred and two years later, the company he built does $16 billion a year.
I walked into a restaurant restroom last week. Mounted on the wall — an Ecolab soap dispenser. White label, small logo. I had seen it a thousand times without thinking about it. Then I looked in the kitchen on my way out. The cleaning chemicals under the sink — Ecolab. The water treatment system feeding the dishwasher — Ecolab. The pest control service log by the back door — Ecolab. One company. Every surface in the building.
Most people think Ecolab is a cleaning supply company. It is not. It is a subscription machine. The chemicals are just the way in. What Ecolab actually sells is a system — dispensers bolted to the wall, service technicians who visit on a schedule, water monitoring sensors, digital dashboards that track usage and compliance. Once the hardware is installed and the staff is trained, switching means ripping out equipment, retraining employees, and risking a health inspection during the gap. Nobody does it.
Osborn's first product cleaned hotel carpets. His second — a non-sudsing compound called Soilax — went into the mechanical dishwashers that restaurants were starting to use in 1924. He added dispensers in 1928. The pattern was set from the beginning: product, equipment, service, repeat. The company renamed itself Ecolab in 1986, went public in 1957, and in 2011 acquired Nalco — the world's largest water treatment company — for roughly $8 billion. That deal turned Ecolab from a hospitality supplier into a global industrial utility.
Here is the math. In fiscal 2025, Ecolab reported $16.1 billion in net sales. Net income reached $2.1 billion. Cash from operations hit $2.95 billion. The company employs 48,000 people — most of them field technicians driving branded trucks to customer sites on fixed routes. It operates in more than 170 countries and roughly 40 industries. Ecolab's own estimate is that it touches a third of the world's processed food supply. And through it all, the company has raised its dividend every single year for 34 consecutive years.
|
The Key To This $560B Market Is In Your Bloodstream
Today, over half a billion people battle osteoarthritis*, a disease that leads to joint degradation and, eventually, immobility. It’s a $560B annual market, but not a single therapy has been able to actually stop OA.
It turns out the answer has been inside us all along.
A startup named Cytonics discovered that the human body already produces a protein designed to protect cartilage. It just doesn’t produce enough where it's needed most. So Cytonics harnessed it.
Their first-generation therapy has already treated 10,000+ patients. Now they've engineered a 200% more potent, mass-producible version pushing toward FDA approval.
But that's only scratching the surface of why 7,000+ investors have already backed Cytonics.
Breakthrough: If approved, Cytonics treatment could be the first true disease-modifying treatment for osteoarthritis in history.
Traction: With a Phase 1 human safety trial completed with zero adverse events, Cytonics has the clinical proof to back their science.
Now’s your chance to claim a piece at the pre-clinical stage as an early-stage shareholder. Invest in Cytonics before the opportunity ends later this month.
That 34-year dividend streak tells you something about the customer relationship. Recessions come. Restaurants close. Hotels go dark. But the ones that survive keep paying Ecolab — because the alternative is a dirty kitchen, a failed health inspection, or a water system that fouls a production line. This is not optional spending. It is the cost of staying open.
The pricing power lives in the model, not the product. Ecolab does not sell you a jug of soap and walk away. It installs a dispenser that meters the exact dose. It sends a technician on a fixed schedule to refill, inspect, and adjust. It layers in digital monitoring — sensors that track water usage, chemical concentration, and temperature in real time. Each layer adds cost to the customer. Each layer makes leaving harder. The chemicals themselves might be commodity inputs. The system is not.
Christophe Beck — Ecolab's chairman and CEO since 2020 — put the strategy plainly in the company's first-quarter 2026 earnings release: "We delivered another strong quarter, with accelerated sales growth and double-digit earnings growth reflecting the strength of our growth engines." Under Beck, the company has pushed hard into what it calls Ecolab Digital — subscriptions for monitoring hardware and software that sit on top of the chemical delivery. In the first quarter of 2026, digital sales grew 24% to $99 million. That is still a small fraction of total revenue. But it is the fastest-growing piece — and the stickiest.
Here is the part that surprised me. Bill Gates — through his investment vehicle, Cascade Investment — owns roughly 12% of Ecolab. It is one of Cascade's largest positions, held for years. Gates does not talk about it much. But think about what he sees. A company embedded in the physical infrastructure of every restaurant, hospital, factory, and hotel on earth. A subscription model that compounds through route density — more customers per truck per mile. A business so boring it never makes headlines. That is the point.
The flywheel works like the original carpet cleaner. Ecolab enters a customer site with one product — say, warewashing chemicals for the kitchen. The technician visits monthly. Trust builds. Then the customer adds water treatment. Then pest elimination. Then laundry. Then facility care. Each added service runs on the same truck route. Revenue per customer rises. Cost per delivery drops. Ecolab's four segments — Water, Institutional and Specialty, Life Sciences, and Pest Elimination — are not separate businesses. They are four lines on the same invoice.
WHY THIS WORKS
Infrastructure-level stickiness. Dispensers are bolted to walls. Sensors are wired into water systems. Staff is trained on Ecolab protocols. Ripping it out means downtime and risk.
Route density compounds. 48,000 associates serve millions of locations on fixed routes. Each new customer on an existing route lowers cost and raises margin.
Recession-resistant demand. Restaurants, hospitals, and factories must stay clean to stay open. Health codes do not take recessions off.
The razor-and-blade model at industrial scale. The dispenser is the razor. The chemical refill, the service visit, and the data subscription are the blades — delivered on a schedule, billed on a contract.
What most people miss: Ecolab has paid a cash dividend on its common stock for more than 88 consecutive years — without interruption — through the Great Depression, World War II, every recession, and a global pandemic. Bill Gates quietly owns 12% of it. And the company's name is on the soap dispenser you used this morning without looking up.
*Disclaimer:
Source: The Lancet Rheumatology*
This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/
Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal


